Renting the Molecule Factory: Pierre Fabre, XtalPi and Mid-Sized Pharma's AI Bet
Dr. Dereck Mush, MD, MBA
What they do
DeepLife develops AI virtual cell models for drug discovery. 3billion's primary announcement, dated November 10, 2026, describes a Master Co-Development Agreement combining genomic evidence with virtual cell models to identify therapeutic targets and develop drug candidates. Jonathan Baptista is DeepLife's co-founder and CEO. The collaboration is research and development, not a clinical efficacy result.
People in this update
- Jonathan BaptistaCo-founder and CEOSource
The record
- Vertical
- Biotech & Drug Discovery
- Sub-segment
- AI virtual cell models
- Product type
- Platform software
- Stage
- Headquarters
- Not disclosed
- Region
- Europe
- Founded
- Not disclosed
- Total funding
- Undisclosed
Also in Biotech & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA
Buying Second Chances: Biossil, Theriva and the AI-Native Bet on Shelved Drugs
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA